About CA125 + HE4


Know the right treatment path.

The path to more optimal patient outcomes begins with the new
CA125 + HE4 risk stratification tool.

HE4 is a novel serum biomarker that when combined with CA125™ significantly raises the level of sensitivity for the determination of risk of malignancy in patients presenting with a pelvic mass. HE4 is consistently expressed in patients with ovarian cancer, and it has demonstrated increased sensitivity and specificity over that of CA125 alone.

The new CA125 + HE4 risk stratification tool is a new differential diagnostic for women presenting with pelvic mass to help determine the most appropriate course of care. It is designed to measure levels of the CA125 and HE4 proteins in the blood to aid in the risk stratification of women who present with pelvic mass.21

Read more about CA125 + HE4.

View a selection of CA125 + HE4 clinical studies.